Oxford Biomedica (LON:OXB) Cut to “Hold” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft cut shares of Oxford Biomedica (LON:OXB) to a hold rating in a report published on Tuesday morning,Digital Look reports. The brokerage currently has GBX 595 price objective on the biopharmaceutical company’s stock, down from their prior price objective of GBX 800.

Several other research firms have also issued reports on OXB. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 8.27 price target on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Royal Bank Of Canada decreased their price objective on Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating for the company in a report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Oxford Biomedica currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 580.85.

Oxford Biomedica Stock Up 0.8%

Shares of Oxford Biomedica stock opened at GBX 507 on Tuesday. The firm’s 50 day moving average price is GBX 581.71 and its 200-day moving average price is GBX 624.39. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16. Oxford Biomedica has a 52-week low of GBX 441.50 and a 52-week high of GBX 952. The company has a market cap of £613.66 million, a P/E ratio of -18.83 and a beta of 1.10.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.